CliffBio
small molecule

RECLAST

ZOLEDRONIC ACID

Loss of exclusivityAugust 2028latest FDA-listed patent expiry
CompanySandoz →See this company's full patent-cliff portfolio

Drug detail

Brand nameRECLAST
Active ingredientZOLEDRONIC ACID
StrengthEQ 5MG BASE/100ML
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalApril 2007
Marketing statusRX

Listed patents

PatentExpiresType
7932241*PEDAugust 2028—
7932241February 2028product

More from Sandoz

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RECLAST patent cliff — loss of exclusivity August 2028 | CliffBio